EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vaginal oxygen and hyaluronic acid for genito-urinary symptoms of breast cancer survivors. One-year follow-up study

Angelo Cagnacci, Giorgia Asinaro, Giorgia Spirito-Rosevich, Matteo Lambertini, Lucia del Mastro, Ambrogio Pietro Londero, Claudia Massarotti

Frontiers in Reproductive Health · 20.11.2026 · 8

DOI: 10.3389/frph.2026.1995703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Reproductive Health, online erschienen am 20.11.2026. Verfasst von Angelo Cagnacci und 6 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds To investigate in breast cancer survivors on adjuvant hormone therapy the persistence up to 1 year of the modifications of genito-urinary symptoms associated with the use of vaginal oxygen and hyaluronic acid.

Methods

Single centre prospective observational study with a follow-up period of 12 months performed on women enrolled between July 2020 and July 2024. Each woman every 15 days for 5 times received an applications of vaginal oxygen and hyaluronic acid. At each single treatment intravaginal oxygen was administered for 15 min. In the last 5 min oxygen was co-administered with a 0.2% sodium hyalurate solution. Modifications associated with treatments were evaluated at the end of treatment and 1, 3 and 12 months since treatment termination. The modification of the vaginal health index score (VHIS) was the primary objective of the study. Secondary objectives were modifications of the visual analogue scale value (VAS) of vaginal burning and dyspareunia, of the female sexual function inventory score (FSFI) and of the short-form of the urinary distress inventory-6 score (UDI-6).

Results

Sixty-five breast cancer survivors were included between July 2021 and July 2024. During treatment we observed an improvement ( p = 0.005) of VHIS and FSFI, and a decrease ( p = 0.005) of dyspareunia, burning and UDI-6 score. After 12 months VHIS (13.4 ± 2.5 vs. 9.6 ± 2.5) and FSFI (13.9 ± 9.5 vs. 10.0 ± 7.4), remained higher ( p = 0.005), dyspareunia (6.5 ± 2.8 vs. 8.7 ± 1.4 p = 0.005) and burning (3.4 ± 3.1 vs. 6.1 ± 2.7) lower ( p = 0.005) than at baseline, while the UDI-6 scores returned to baseline values.

Conclusions

Genito-urinary symptoms of breast cancer survivors on adjuvant endocrine therapy improved following vaginal oxygen and hyaluronic acid. After 12 months improvements were conserved on sexuality, attenuated on vaginal atrophy, dyspareunia and vaginal burning, and lost on lower urinary tract disturbances.

Zitieren

APA

Cagnacci, A., Asinaro, G., Spirito-Rosevich, G., Lambertini, M., Mastro, L. D., Londero, A. P., & Massarotti, C. (2026). Vaginal oxygen and hyaluronic acid for genito-urinary symptoms of breast cancer survivors. One-year follow-up study. Frontiers in Reproductive Health, 8. https://doi.org/10.3389/frph.2026.1995703

Vancouver

Cagnacci A, Asinaro G, Spirito-Rosevich G, Lambertini M, Mastro LD, Londero AP, et al. Vaginal oxygen and hyaluronic acid for genito-urinary symptoms of breast cancer survivors. One-year follow-up study. Frontiers in Reproductive Health. 2026;8. doi:10.3389/frph.2026.1995703

BibTeX
@article{Cagnacci2026,
  author = {Cagnacci, Angelo and Asinaro, Giorgia and Spirito-Rosevich, Giorgia and Lambertini, Matteo and Mastro, Lucia del and Londero, Ambrogio Pietro and Massarotti, Claudia},
  title = {Vaginal oxygen and hyaluronic acid for genito-urinary symptoms of breast cancer survivors. One-year follow-up study},
  journal = {Frontiers in Reproductive Health},
  year = {2026},
  volume = {8},
  doi = {10.3389/frph.2026.1995703}
}
Kostenlos starten →